This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Cambridge Isotope Laboratories Selects Accelrys Lab Automation Software For Improved Quality Control And Regulatory Compliance

Stocks in this article: ACCL

SAN DIEGO, Aug. 28, 2013 /PRNewswire/ --  Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, announced today that Cambridge Isotope Laboratories, Inc. (CIL) is deploying the Accelrys Laboratory Execution System (LES) and three applications within the Accelrys Laboratory Information Management System (LIMS) to enhance quality control and regulatory compliance as the company experiences increased demand for its products. The full enterprise deployment of these applications, which are a part of the Accelrys Process Management and Compliance Suite, is progressing well following the successful completion of a comprehensive pilot. The pilot phase resulted in a 28 percent improvement in productivity or test execution time and a 78 percent reduction in data review times, ultimately enabling CIL to improve lab processing time by 40 percent.

Sample Management: A Process Capability Analysis of the protein concentration of a bio-pharmaceutical process. This analysis shows that 14% of the batches will fall outside the specification limits if the process is continued in the current state.

"As a world leader in the production of stable isotope applications, CIL understands that developing and commercializing innovative products in an efficient, cost-effective and compliant manner requires an entirely new approach to the lab-to-commercialization process," said Ken Rapp, managing director of Accelrys' analytical, development, quality and manufacturing solutions group. "By connecting lab-to-plant workflows and taking a process- and execution-centric approach to LIMS implementations, CIL benefits from the flexibility needed to manage its rapidly growing business and the highly efficient process execution required to produce quality cGMP products."

CIL develops, produces and markets stable, non-radioactive isotopes and chemical components for the specialty chemicals, research products, environmental standards and clinical research industries. Producing products that meet cGMP requirements is essential to its business. GMP compliance is an expensive and time-consuming practice, and with customer demand driving increasing production, CIL's manual processes were no longer keeping pace with the company's needs.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs